UroGen Pharma Ltd. Quarterly Operating Income (Loss) in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
UroGen Pharma Ltd. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2017 to Q3 2024.
  • UroGen Pharma Ltd. Operating Income (Loss) for the quarter ending September 30, 2024 was -$17.5M, a 30% decline year-over-year.
  • UroGen Pharma Ltd. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$83.7M, a 17.6% decline year-over-year.
  • UroGen Pharma Ltd. annual Operating Income (Loss) for 2023 was -$65.5M, a 17.1% increase from 2022.
  • UroGen Pharma Ltd. annual Operating Income (Loss) for 2022 was -$79M, a 14.4% increase from 2021.
  • UroGen Pharma Ltd. annual Operating Income (Loss) for 2021 was -$92.3M, a 27.2% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$83.7M -$17.5M -$4.05M -30% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$79.7M -$25.8M -$10.5M -68% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$69.2M -$25.7M -$3.7M -16.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$65.5M -$14.6M +$5.67M +28% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 -$71.2M -$13.5M +$4.59M +25.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$75.8M -$15.4M +$3.33M +17.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$79.1M -$22M -$88K -0.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$79M -$20.3M -$367K -1.84% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 -$78.7M -$18.1M +$5.35M +22.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$84M -$18.7M +$4.11M +18% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$88.1M -$22M +$4.16M +15.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$92.3M -$19.9M +$7.34M +26.9% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-24
Q3 2021 -$99.6M -$23.4M +$5.68M +19.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$105M -$22.8M +$8.98M +28.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$114M -$26.1M +$12.4M +32.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$127M -$27.3M +$12.6M +31.6% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-21
Q3 2020 -$139M -$29.1M -$5.67M -24.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$134M -$31.8M -$8.05M -33.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 -$126M -$38.6M -$16.1M -71.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 -$109M -$39.8M -$15.8M -65.9% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-02
Q3 2019 -$93.7M -$23.5M -$2.36M -11.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$91.3M -$23.8M -$5.32M -28.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 -$86M -$22.4M -$8.79M -64.5% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$77.2M -$24M -$13.9M -136% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-02
Q3 2018 -$63.3M -$21.1M -$20.8M -6860% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-02
Q2 2018 -$42.5M -$18.4M -$12.5M -210% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-02
Q1 2018 -$30.1M -$13.6M -$10.1M -286% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-02
Q4 2017 -$20M -$10.2M Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 -$303K Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 -$5.95M Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 -$3.54M Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.